[go: up one dir, main page]

FR17C1011I2 - PROTEASOME INHIBITORS - Google Patents

PROTEASOME INHIBITORS

Info

Publication number
FR17C1011I2
FR17C1011I2 FR17C1011C FR17C1011C FR17C1011I2 FR 17C1011 I2 FR17C1011 I2 FR 17C1011I2 FR 17C1011 C FR17C1011 C FR 17C1011C FR 17C1011 C FR17C1011 C FR 17C1011C FR 17C1011 I2 FR17C1011 I2 FR 17C1011I2
Authority
FR
France
Prior art keywords
proteasome inhibitors
proteasome
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR17C1011C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38691782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR17C1011(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of FR17C1011I1 publication Critical patent/FR17C1011I1/fr
Application granted granted Critical
Publication of FR17C1011I2 publication Critical patent/FR17C1011I2/en
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR17C1011C 2007-08-06 2017-04-14 PROTEASOME INHIBITORS Active FR17C1011I2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/017440 WO2009020448A1 (en) 2007-08-06 2007-08-06 Proteasome inhibitors

Publications (2)

Publication Number Publication Date
FR17C1011I1 FR17C1011I1 (en) 2017-05-26
FR17C1011I2 true FR17C1011I2 (en) 2018-04-27

Family

ID=38691782

Family Applications (1)

Application Number Title Priority Date Filing Date
FR17C1011C Active FR17C1011I2 (en) 2007-08-06 2017-04-14 PROTEASOME INHIBITORS

Country Status (32)

Country Link
EP (3) EP3210987A1 (en)
JP (1) JP5261488B2 (en)
KR (6) KR20150010802A (en)
CN (1) CN101772507B (en)
AU (1) AU2007357338B2 (en)
BR (1) BRPI0721905B8 (en)
CA (1) CA2695082C (en)
CY (2) CY1113386T1 (en)
DK (1) DK2178888T3 (en)
EA (1) EA028622B1 (en)
EC (1) ECSP10010015A (en)
ES (1) ES2390606T3 (en)
FR (1) FR17C1011I2 (en)
GE (1) GEP20125599B (en)
HR (1) HRP20120745T1 (en)
HU (1) HUS1700018I1 (en)
IL (4) IL203641A (en)
LT (1) LTC2178888I2 (en)
LU (1) LUC00013I2 (en)
MY (1) MY161991A (en)
NL (1) NL300871I2 (en)
NZ (1) NZ582693A (en)
PH (1) PH12014500053B1 (en)
PL (1) PL2178888T3 (en)
PT (1) PT2178888E (en)
RS (1) RS52435B (en)
SG (1) SG10201508712QA (en)
SI (1) SI2178888T1 (en)
TN (1) TN2010000060A1 (en)
UA (1) UA97536C2 (en)
WO (1) WO2009020448A1 (en)
ZA (1) ZA201000348B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
KR101434522B1 (en) 2005-11-09 2014-08-26 오닉스 세라퓨틱스, 인크. Compounds for enzyme inhibition
RU2450016C2 (en) 2006-06-19 2012-05-10 Протеоликс, Инк. Peptide epoxy ketones for proteasome inhibition
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
SI2207791T2 (en) 2007-10-04 2019-09-30 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
US20090325903A1 (en) 2008-06-17 2009-12-31 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
AR075090A1 (en) 2008-09-29 2011-03-09 Millennium Pharm Inc ACID DERIVATIVES 1-AMINO-2-CYCLLOBUTILETILBORONICO PROTEOSOMA INHIBITORS, USEFUL AS ANTI-BANKER AGENTS, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM.
EP2796134B1 (en) 2008-10-21 2016-12-07 Onyx Therapeutics, Inc. Combination of the peptide epoxyketone proteasome inhibitor carfilzomib with melphalan for use in the treatment of multiple myeloma
AR075899A1 (en) 2009-03-20 2011-05-04 Onyx Therapeutics Inc PROTEASA INHIBITING CRYSTALLINE EPOXYCETON TRIPEPTIDES
EP2498793B1 (en) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib for use in metastasis suppression
WO2011087822A1 (en) 2009-12-22 2011-07-21 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
US8513218B2 (en) 2010-03-31 2013-08-20 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
CA2833775A1 (en) * 2011-06-22 2012-12-27 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
HUE060305T2 (en) * 2011-08-30 2023-02-28 Tufts College Fap-activated proteasome inhibitors for treating solid tumors
MX352652B (en) * 2011-12-22 2017-12-04 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors.
US20160008382A1 (en) * 2012-01-24 2016-01-14 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
US20140357596A1 (en) * 2012-01-24 2014-12-04 Millennium Pharmaceuticals, Inc. Method of treatment of nasopharyngeal cancer
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
CN103570806B (en) * 2012-07-26 2020-04-07 圣特莱国际公司 Polypeptide epoxy ketone compound
JP2013006855A (en) * 2012-09-03 2013-01-10 Millennium Pharmaceuticals Inc Proteasome inhibitor
CN104822689B (en) * 2012-12-03 2016-11-02 弗·哈夫曼-拉罗切有限公司 Substituted triazole boronic acid compounds
WO2015051067A1 (en) 2013-10-03 2015-04-09 Millennium Pharmaceuticals, Inc. Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis
WO2015179443A1 (en) 2014-05-20 2015-11-26 Millennium Pharmaceuticals. Inc. Boron-containing proteasome inhibitors for use after primary cancer therapy
US10301273B2 (en) 2014-08-07 2019-05-28 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
MA41555A (en) * 2015-02-17 2017-12-26 Millennium Pharm Inc POLYTHERAPY FOR CANCER TREATMENT
US10144761B2 (en) 2015-06-19 2018-12-04 Hanlin Scientific Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
CN106608883A (en) * 2015-10-21 2017-05-03 北京大学 Synthetic method of proteasome inhibitor MLN9708
WO2017198194A1 (en) * 2016-05-19 2017-11-23 成都奥璟生物科技有限公司 Boronic acid and borate ester compound and applications thereof
CN106008572B (en) * 2016-05-23 2018-08-17 成都千禧莱医药科技有限公司 A kind of dipeptide boronic acid compound and preparation method and purposes
WO2017222914A1 (en) 2016-06-21 2017-12-28 Inception 4, Inc. Carbocyclic prolinamide derivatives
EP3472149B1 (en) 2016-06-21 2023-08-30 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
JP6802899B2 (en) * 2016-07-25 2020-12-23 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Shenzhen TargetRx,Inc. Substituted boronic acid compounds, pharmaceutical compositions containing the compounds and their use
WO2018133661A1 (en) * 2017-01-23 2018-07-26 成都奥璟生物科技有限公司 Novel boric acid derivative and pharmaceutical composition using same
US11596629B2 (en) 2017-02-28 2023-03-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
CN108794516A (en) * 2017-04-26 2018-11-13 上海时莱生物技术有限公司 Boric acid and boric acid ester compound and its preparation method and application
US11414437B2 (en) 2017-07-28 2022-08-16 Chengdu Origin Biotechnology Limited Company Borate compound, and synthesis method therefor and uses thereof
ES2901022T3 (en) 2017-08-25 2022-03-21 Synthon Bv Procedure for the preparation of ixazomib and its intermediates
JP2018024694A (en) * 2017-10-03 2018-02-15 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Proteasome inhibitor
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
CN110903310B (en) 2018-09-14 2022-11-22 成都奥璟生物科技有限公司 A kind of boric acid ester drug and its application
CN110357787A (en) * 2019-08-02 2019-10-22 苏州艾和医药科技有限公司 Yi Shazuo meter synthesising process research
EP4041246B1 (en) * 2019-10-07 2024-12-04 Cornell University Antimicrobial and antiviral effects of c2-c7alkyl boronic acids
CN110950897B (en) * 2019-12-12 2021-05-28 山东大学 A kind of histone deacetylase, proteasome dual-target inhibitor and preparation method and application thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (en) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin inhibitors
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
ES2571219T3 (en) * 2001-01-25 2024-09-23 The United States Of America Represented By The Sec Dep Of Health And Human Services Formulation of boronic acid compounds
JP4416501B2 (en) 2001-05-30 2010-02-17 ノバルティス アクチエンゲゼルシャフト 2-{[N- (2-amino-3- (heteroaryl or aryl) propionyl) -aminoacyl] -amino} -alkylboronic acid derivatives
CN1867572B (en) * 2003-08-14 2012-03-28 赛福伦公司 Proteasome inhibitors and methods of use thereof
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
SG10201600029PA (en) 2004-03-30 2016-02-26 Millennium Pharm Inc Synthesis of boronic ester and acid compounds
WO2006008660A2 (en) 2004-07-20 2006-01-26 Affinium Pharmaceuticals, Inc. Streptococcus pneumoniae enoyl- (acyl-carrier-protein) reductase (fabk)
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
GB0513349D0 (en) 2005-06-29 2005-08-03 Torres Manel Non-woven fabric
BRPI0612607A2 (en) 2005-07-05 2010-12-07 Tufts College fibroblast activation alpha protein inhibitors

Also Published As

Publication number Publication date
CY2017016I1 (en) 2017-07-12
GEP20125599B (en) 2012-08-10
EP2178888B1 (en) 2012-07-04
CY2017016I2 (en) 2017-07-12
IL242292A (en) 2017-12-31
IL203641A (en) 2015-11-30
BRPI0721905B8 (en) 2021-05-25
ECSP10010015A (en) 2010-04-30
KR20160040735A (en) 2016-04-14
HUS1700018I1 (en) 2017-05-29
UA97536C2 (en) 2012-02-27
EP3210987A1 (en) 2017-08-30
PH12014500053A1 (en) 2015-03-30
KR20100059811A (en) 2010-06-04
EA201070247A1 (en) 2010-06-30
EP2178888A1 (en) 2010-04-28
IL242291A (en) 2017-12-31
CN101772507A (en) 2010-07-07
IL242291A0 (en) 2015-11-30
LTPA2017010I1 (en) 2017-05-10
CY1113386T1 (en) 2016-06-22
BRPI0721905B1 (en) 2020-11-17
MY161991A (en) 2017-05-31
JP2010535759A (en) 2010-11-25
AU2007357338B2 (en) 2014-03-20
KR20140042933A (en) 2014-04-07
TN2010000060A1 (en) 2011-09-26
SG10201508712QA (en) 2015-11-27
BRPI0721905A2 (en) 2014-02-25
HK1182924A1 (en) 2013-12-13
JP5261488B2 (en) 2013-08-14
CA2695082C (en) 2015-07-28
ES2390606T3 (en) 2012-11-14
LUC00013I1 (en) 2017-04-06
LTC2178888I2 (en) 2018-03-12
PT2178888E (en) 2012-10-04
RS52435B (en) 2013-02-28
KR101474831B1 (en) 2014-12-19
WO2009020448A1 (en) 2009-02-12
DK2178888T3 (en) 2012-10-01
KR20150010802A (en) 2015-01-28
AU2007357338A1 (en) 2009-02-12
CA2695082A1 (en) 2009-02-12
IL242290A (en) 2017-12-31
CN101772507B (en) 2012-12-12
KR101831674B1 (en) 2018-02-23
PL2178888T3 (en) 2012-11-30
KR20140042932A (en) 2014-04-07
LUC00013I2 (en) 2017-06-19
SI2178888T1 (en) 2012-11-30
ZA201000348B (en) 2011-03-30
EA028622B1 (en) 2017-12-29
EP2527347A1 (en) 2012-11-28
PH12014500053B1 (en) 2015-03-30
HK1143595A1 (en) 2011-01-07
IL242290A0 (en) 2015-11-30
HRP20120745T1 (en) 2012-10-31
NL300871I2 (en) 2017-12-07
NZ582693A (en) 2012-01-12
IL242292A0 (en) 2015-11-30
KR20170004031A (en) 2017-01-10
FR17C1011I1 (en) 2017-05-26

Similar Documents

Publication Publication Date Title
FR17C1011I2 (en) PROTEASOME INHIBITORS
CY2020024I1 (en) BETA-LACTAMAS INHIBITORS
BRPI0807547A2 (en) HYPERCYCLIC ASPARTIL PROTEASE INHIBITORS
CR10831A (en) ESPIRO KETONA ACETIL-CoA CARBOXILASA INHIBITORS
DK2041138T3 (en) PYRROLTRIAZINKINASE INHIBITORS
DK2024375T3 (en) Cyclopropyl-condensed indolobenzazepine-HCV-NS5B inhibitors
IT1394247B1 (en) TIGHTENING DEVICE
BRPI0810365A2 (en) INDOL 7-REPLACED MLC-1 INHIBITORS
BRPI0814797A2 (en) DNA-PK INHIBITORS
BRPI0918564A2 (en) inhibitors
BRPI0807772A2 (en) PACKING DEVICE
BRPI0912234A2 (en) salinosporamide derivatives as proteasome inhibitors
FI20085565A0 (en) sealing device
AT506380A3 (en) STAMP DEVICE
DE602009001221D1 (en) sealing device
DK2066662T3 (en) SERINHYDROLASE INHIBITORS
EP2435048A4 (en) RADIO-MARKED PDE10 INHIBITORS
BRPI0918966A2 (en) protease inhibitors
NO20070960A (en) Teine
BRPI0919073A2 (en) protease inhibitors
FI20075320A0 (en) New useful inhibitors
FI20075579L (en) Holding device
GB0707315D0 (en) Novel proteasome inhibitor
ITMI20061754A1 (en) PERFORMED BEVELING DEVICE